Ralf Lutterbuese

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Max S. Topp, Peter Kufer, Nicola Gökbuget et al. · Journal of Clinical Oncology · 2011 · 913 citations · Full text

Medicine, Hematology, Oncology +16

MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors

Klaus Brischwein, Bernd Schlereth, Benjamin Guller et al. · Molecular Immunology · 2005 · 260 citations

Pharmacy, Medicinal Chemistry, Oncology +14

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

Ralf Lutterbuese, Tobias Raum, Roman Kischel et al. · Proceedings of the National Academy of Sciences · 2010 · 167 citations

Medicine, Oncology, Pharmacology +17

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

Matthias Friedrich, Tobias Raum, Ralf Lutterbuese et al. · Molecular Cancer Therapeutics · 2012 · 146 citations

Life Sciences, Immunology, Oncology +17

Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct

Bernd Schlereth, Iduna Fichtner, Grit Lorenczewski et al. · Cancer Research · 2005 · 130 citations

Life Sciences, Immunology, Oncology +16